FDA Grants Accelerated Approval to Sevabertinib for Non-Squamous NSCLC By Ogkologos - November 27, 2025 245 0 Facebook Twitter Google+ Pinterest WhatsApp It also approved a companion diagnostic device to aid in detecting HER2 tyrosine kinase domain activating mutations Source RELATED ARTICLESMORE FROM AUTHOR New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC MOST POPULAR FDA Approves Ciltacabtagene Autoleucel for Relapsed or Refractory Multiple Myeloma March 25, 2022 Navigating Your Care During Long-Term Cancer Survivorship June 25, 2020 NEOSTAR Results Indicate that Neoadjuvant Nivolumab Plus Ipilimumab Enhances Pathologic Responses... March 9, 2021 Pembrolizumab Combined with Chemoradiotherapy Improves PFS in Women with Newly Diagnosed,... March 27, 2024 Load more HOT NEWS Fosnetupitant Is Valuable in the Prophylaxis of Acute, Delayed, and Beyond... An Increase in Healthcare Costs Associated with the Use of Multigene... Neoadjuvant Dabrafenib Plus Trametinib Has High Pathological Response Rates in Clinical... Survivor Sees Mom Fighting Breast Cancer At Brunch And Pays For...
